A Phase II, Randomized, Double-Blind Study of the Use of Rucaparib vs. Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2019
Price : $35 *
At a glance
- Drugs Rucaparib (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- 07 Mar 2019 Status changed from not yet recruiting to recruiting.
- 14 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Jun 2019.
- 30 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Dec 2018.